Evogene Expands Biofuel Activity in Brazil with SLC Agricola
Expanded Agreement follows Successful Completion of Field Trials
Evogene Ltd. and SLC Agricola announced expansion of their agreement for the development of castor bean seeds as a cost competitive feedstock for biofuels. This expansion follows successful completion of field trials for such varieties in northeast Brazil during 2011.
The collaboration between Evogene and SLC Agricola, initiated in 2010, is focused on developing advanced castor seed displaying high oil yield under rain-fed conditions and suitable for sustainable and commercial production in Brazil. In recently completed field trials, proprietary castor varieties developed by Evogene demonstrated improved yield potential and performance compared to existing cultivars. Under the expanded agreement, the companies will continue to collaborate on evaluating Evogene's castor varieties in SLC's farm locations in northeast Brazil to determine the best performing varieties and agronomic practices suitable for commercial scale production.
About SLC Agricola SLC Agricola SA. is one of the largest land owners and agricultural producers in Brazil, being also the first in its sector (grains and cotton) to list its shares in a stock exchange. It focuses of the production of cotton, soybean and corn, and also on the acquisition and development of farmland in the country for future sale. The Company currently operates 13 production units, in six different states, totaling 250 thousand hectares of planted area at the 2011/12 crop year. The Company’s business model is based on a large-scale, modern production system, with standardized production units, thoroughly up-to-date technology and rigorous cost controls, underpinned by social and environmental responsibility.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Helping the body overcome Sars-Cov-2 - Therapeutic application of certain interferon-alpha subtypes supports the host’s defence against Sars-Cov-2
Herpes_simplex_virus

Serotonin mediates exercise-induced generation of new neurons

Biomarker helps identify 'window of opportunity' for cancer chemotherapy timing
The Wistar Institute - Philadelphia, USA
First single-enzyme method to produce quantum dots revealed
Breaching the blood-brain barrier to create powerful new tools for fighting cancer - Researchers at Rensselaer Polytechnic Institute are developing new technology for pushing drugs through the blood-brain barrier, directly targeting brain tumors
Nautilus Biotech and Creabilis Therapeutics Achieve Technical Milestone in Collaboration - Improvement of HMGB1 Box A for the Treatment of Rage- and HMGB1-Related Pathologies
